MEDIROM Healthcare Technologies Has Received Orders for Over 25,000 MOTHER Bracelet Units
TOKYO, Dec. 09, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (“MEDIROM”) announces that its subsidiary MEDIROM MOTHER...
Staff
Medigene AG Announces KRAS G12V as First Target for TCR-guided T Cell Engagers
Planegg/Martinsried, December 9, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on...
Nikon and eLabNext collaborate to integrate the NIS-Elements imaging platform with eLabNext’s Digital Lab Platform in the US
FRAMINGHAM, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Nikon and eLabNext partner to enhance data integration between NIS-Elements imaging software...
DARZALEX® (daratumumab) SC-based regimens improve MRD negativity and progression-free survival in newly diagnosed multiple myeloma, and overall survival in AL amyloidosis
New analysis from Phase 3 CEPHEUS study demonstrates 85 percent of patients who achieved MRD negativity (10-6) with daratumumab SC...
Scryb Announces Sale of its Joint Venture Interest in Fionet Rapid Response Group for CAD$3.5 million plus a Royalty
Toronto, Ontario--(Newsfile Corp. - December 9, 2024) - Scryb Inc. (CSE: SCYB) (OTCQB: SCYRF) (FSE: EIY) ("Scryb'' or the "Company") is pleased to...
BioGene Therapeutics Appoints Patroski J. Lawson to Board of Directors
Vancouver, British Columbia--(Newsfile Corp. - December 9, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) ("PreveCeutical" or the...
Tinley’s Provides Corporate Update and Announces Results of Its 2024 Annual and Special Meeting of Shareholders
Toronto, Ontario and Los Angeles, California--(Newsfile Corp. - December 9, 2024) - The Tinley Beverage Company Inc. (CSE: TNY) (OTCQB:...
AngioDynamics Receives FDA Clearance for The NanoKnife® System for Prostate Tissue Ablation
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in...
Prezent Sets New Milestones with Record Revenue in 2024, Unveils AI-Driven Vision for Enterprise Communication, and Secures Backing from New Investors True Global Ventures and Zoom Ventures to Accelerate Hyper-Growth in 2025
LOS ALTOS, Calif., Dec. 9, 2024 /PRNewswire/ -- Prezent, the Enterprise Business Storytelling Platform, announced today multiple key milestones achieved in...
Bioz Stars Awards 2024: Recognizing the World’s Top Suppliers in Scientific Innovation
PALO ALTO, CA / ACCESSWIRE / December 9, 2024 / Bioz, Inc, a leader in AI-powered solutions for scientific research,...
CeraVx B.V. Emerges from Stealth Acquires Micro Needle Technology from MLT Appoints Management and Supervisory Board
CeraVx BV successful bid to acquire key micro needle technology from MLTManagement team:Dr. Jan Groen as CEO,Dinja Oosterhof , PhD...
BioNxt Solutions Reports Progress on BNT23001 Development for Multiple Sclerosis Treatment
VANCOUVER, BC / ACCESSWIRE / December 9, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience...
Hemogenyx Pharmaceuticals PLC Announces Site Initiation Visit Completed
Hemogenyx Pharmaceuticals Successfully Completes the Site Initiation Visit of the First Clinical Site for Phase I Clinical Trial of HG-CT-1...
Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program Update
- Data from long-term follow-up of patients in clinical trials further demonstrate durability of the transformative benefits of CASGEVY™ -...
Scryb Launches New AI Governance Technology Business Unit, ‘Raidian’
Toronto, Ontario--(Newsfile Corp. - December 8, 2024) - Scryb Inc. (CSE: SCYB) (OTCQB: SCYRF) (FSE: EIY) ("Scryb'' or the "Company"), is pleased...
Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
Media ReleaseCOPENHAGEN, Denmark; December 7, 2024 Results show 96 percent overall response rate (ORR), 87 percent complete response (CR), and...
Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab
Head-to-head exploratory cohort of a Phase 3 trial showed first-in-class poze-cemdi combination treatment helped patients achieve and maintain greater disease...
Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions
New data demonstrate the actionability of clonoSEQ for tailoring treatment decisions in patients with MCL, CLL, MM and ALL Studies...
Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
Data from the ongoing Phase 1/2 ATALANTA-1 study in a heavily pretreated R/R NHL patient population demonstrate high antitumor activity...
Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting
NEW YORK, Dec. 07, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical...